[go: up one dir, main page]

PT922226E - Processo para a avaliacao do estado de um organismo por meio de medicao de peptideos - Google Patents

Processo para a avaliacao do estado de um organismo por meio de medicao de peptideos

Info

Publication number
PT922226E
PT922226E PT97918977T PT97918977T PT922226E PT 922226 E PT922226 E PT 922226E PT 97918977 T PT97918977 T PT 97918977T PT 97918977 T PT97918977 T PT 97918977T PT 922226 E PT922226 E PT 922226E
Authority
PT
Portugal
Prior art keywords
organism
evaluation
state
medication
peptide
Prior art date
Application number
PT97918977T
Other languages
English (en)
Inventor
Wolf-Georg Forssmann
Peter Schulz-Knappe
Michael Schrader
Hans-Georg Opitz
Original Assignee
Biovision Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26028345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT922226(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1996132521 external-priority patent/DE19632521A1/de
Application filed by Biovision Ag filed Critical Biovision Ag
Publication of PT922226E publication Critical patent/PT922226E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
    • Y10T436/255—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] including use of a solid sorbent, semipermeable membrane, or liquid extraction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT97918977T 1996-08-13 1997-08-13 Processo para a avaliacao do estado de um organismo por meio de medicao de peptideos PT922226E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1996132521 DE19632521A1 (de) 1996-08-13 1996-08-13 Verfahren zur Gewinnung von Peptiden aus Köperflüssigkeiten und Geweben sowie Zellüberständen und zur Identifikation von krankheitsrelevanten Peptidmarkern
DE19725362 1997-06-16

Publications (1)

Publication Number Publication Date
PT922226E true PT922226E (pt) 2003-07-31

Family

ID=26028345

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97918977T PT922226E (pt) 1996-08-13 1997-08-13 Processo para a avaliacao do estado de um organismo por meio de medicao de peptideos

Country Status (16)

Country Link
US (1) US6875616B1 (pt)
EP (1) EP0922226B2 (pt)
JP (1) JP2001508864A (pt)
CN (1) CN1233326A (pt)
AT (1) ATE234469T1 (pt)
AU (1) AU720626B2 (pt)
CA (1) CA2263443C (pt)
CZ (1) CZ294729B6 (pt)
DE (1) DE59709517D1 (pt)
DK (1) DK0922226T3 (pt)
EA (1) EA001033B1 (pt)
ES (1) ES2191175T3 (pt)
IS (1) IS4971A (pt)
PL (1) PL186810B1 (pt)
PT (1) PT922226E (pt)
WO (1) WO1998007036A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936424B1 (en) * 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
DE10021737C2 (de) 2000-05-04 2002-10-17 Hermann Haller Verfahren und Vorrichtung zur qualitativen und/oder quantitativen Bestimmung eines Protein- und/oder Peptidmusters einer Flüssigkeitsprobe, die dem menschlichen oder tierischen Körper entnommen wird
US6593298B2 (en) 2001-04-30 2003-07-15 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1690 daltons
US20020160420A1 (en) * 2001-04-30 2002-10-31 George Jackowski Process for diagnosis of physiological conditions by characterization of proteomic materials
US7015004B2 (en) 2001-11-23 2006-03-21 Syn X Pharma, Inc. Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistance
US6620786B2 (en) 2001-04-30 2003-09-16 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having molecular weight of 2937 daltons
US6703366B2 (en) 2001-04-30 2004-03-09 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1,896 daltons
US20020160533A1 (en) 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular of weight of 1525 daltons
US6677303B2 (en) 2001-04-30 2004-01-13 Syn X Pharma Biopolymer marker indicative of disease state having a molecular weight of 1097 daltons
US7294688B2 (en) 2001-04-30 2007-11-13 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
US6599877B2 (en) 2001-04-30 2003-07-29 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1020 daltons
US7314717B2 (en) 2001-04-30 2008-01-01 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons
US6617308B2 (en) 2001-04-30 2003-09-09 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
US6756476B2 (en) 2001-04-30 2004-06-29 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons
US7008800B2 (en) 2001-04-30 2006-03-07 Artemis Proteomics, Ltd. Biopolymer marker indicative of disease state having a molecular weight of 1077 daltons
US6627607B2 (en) 2001-04-30 2003-09-30 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1845 daltons
US6620787B2 (en) 2001-04-30 2003-09-16 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 2267 daltons
US6627608B2 (en) 2001-04-30 2003-09-30 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1206 daltons
US6602855B2 (en) 2001-04-30 2003-08-05 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1449 daltons
US6890763B2 (en) 2001-04-30 2005-05-10 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons
US7087435B2 (en) 2001-04-30 2006-08-08 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 2753 daltons
US7049397B2 (en) 2001-04-30 2006-05-23 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons
US6693080B2 (en) 2001-04-30 2004-02-17 Syn X Pharma Biopolymer marker indicative of disease state having a molecular weight of 1521 daltons
US20040198950A1 (en) 2001-04-30 2004-10-07 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1518 daltons
US6627606B2 (en) 2001-04-30 2003-09-30 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1465 daltons
DE10123711A1 (de) * 2001-05-15 2003-02-27 Wolfgang Altmeyer Verfahren zur Bestimmung der Herkunft biologischer Materialien
US7132244B2 (en) 2001-11-21 2006-11-07 Syn X Pharma, Inc. Betaine/GABA transport protein biopolymer marker indicative of insulin resistance
US7179610B2 (en) 2001-11-23 2007-02-20 Nanogen Inc. Complement C3 precursor biopolymer markers indicative of insulin resistance
US7314762B2 (en) 2001-11-21 2008-01-01 Nanogen, Inc. Apolipoprotein biopolymer markers indicative of insulin resistance
US20030100014A1 (en) * 2001-11-23 2003-05-29 George Jackowski Apolipoprotein biopolymer markers predictive of type II diabetes
US7052849B2 (en) 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
US7074576B2 (en) 2001-11-23 2006-07-11 Syn X Pharma, Inc. Protein biopolymer markers indicative of alzheimer's disease
US7179605B2 (en) 2001-11-23 2007-02-20 Nanogen Inc. Fibronectin precursor biopolymer markers indicative of alzheimer's disease
US7179606B2 (en) 2001-11-23 2007-02-20 Syn X Pharma, Inc. IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
US7094549B2 (en) 2001-11-23 2006-08-22 Syn X Pharma, Inc. Fibronectin biopolymer marker indicative of insulin resistance
US7122327B2 (en) 2001-11-23 2006-10-17 Nanogen Inc. Biopolymer markers indicative of type II diabetes
US7135297B2 (en) 2001-11-23 2006-11-14 Nanogen Inc. Protein biopolymer markers indicative of insulin resistance
AU2002336845A1 (en) * 2001-11-23 2003-06-10 Syn.X Pharma, Inc. Globin biopolymer markers indicative of insulin resistance
US7097989B2 (en) 2001-11-23 2006-08-29 Syn X Pharma, Inc. Complement C3 precursor biopolymer markers predictive of type II diabetes
US6890722B2 (en) 2001-11-23 2005-05-10 Syn X Pharma, Inc. HP biopolymer markers predictive of insulin resistance
US7125678B2 (en) * 2001-11-23 2006-10-24 Nanogen, Inc. Protein biopolymer markers predictive of type II diabetes
US7026129B2 (en) * 2001-11-23 2006-04-11 Syn X Pharma, Inc. IG lambda biopolymer markers predictive of Alzheimers disease
JP2006522340A (ja) 2003-04-02 2006-09-28 メルク　エンド　カムパニー　インコーポレーテッド 質量分析データの分析法
DE10341193A1 (de) * 2003-09-06 2005-03-31 Mosaiques Diagnostics And Therapeutics Ag Vorrichtung und Verfahren zur quantitativen Auswertung der in einer Körperflüssigkeitsprobe enthaltenden Polypeptide sowie Marker zur Erkennung von pathologischen Zuständen
WO2006044666A2 (en) * 2004-10-15 2006-04-27 Northeastern University Detection of disease associated proteolysis by direct mass spectrometry analysis of low molecular weight peptides
WO2009016431A1 (en) * 2007-08-01 2009-02-05 Digilab, Inc. Sample preparation method and apparatus
EP2364447B1 (en) * 2008-10-31 2019-06-12 Biomerieux, Inc Method for the identification of microorganisms
CN102317789B (zh) * 2008-10-31 2014-08-27 生物梅里埃公司 利用质谱法分离、表征和/或鉴定微生物的方法
US9128058B2 (en) * 2008-10-31 2015-09-08 Biomerieux, Inc. Method for separation and characterization of microorganisms using identifier agents
JP6321622B2 (ja) * 2012-03-30 2018-05-09 ビーディー キエストラ ベスローテン フェンノートシャップ 微生物の自動化された選択およびｍａｌｄｉを使用した同定

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5537944A (en) * 1978-09-09 1980-03-17 Seiichi Shibata Diagnosis chemical and diagnosis method of kidney disease
EP0651816A4 (en) * 1992-07-15 1995-10-25 Univ South Florida CONTENT OF CCK PEPTIDES IN FLOWER IN RELATION TO THE TREATMENT OF PANIC RIFLES.
US5492834A (en) * 1993-07-09 1996-02-20 Beckman Instruments, Inc. Method of sample preparation for urine protein analysis with capillary electrophoresis
DE4427531A1 (de) * 1994-08-04 1996-02-08 Forssmann Wolf Georg Humanes zirkulierendes beta-Defensin hBD-1
JP3579549B2 (ja) * 1995-10-24 2004-10-20 株式会社トクヤマ 糖尿病または糖尿病合併症用マーカーとしての使用

Also Published As

Publication number Publication date
JP2001508864A (ja) 2001-07-03
CA2263443A1 (en) 1998-02-19
DE59709517D1 (de) 2003-04-17
EA199900196A1 (ru) 1999-06-24
CZ49199A3 (cs) 2000-04-12
CZ294729B6 (cs) 2005-03-16
ES2191175T3 (es) 2003-09-01
DK0922226T3 (da) 2003-07-07
WO1998007036A1 (de) 1998-02-19
IS4971A (is) 1999-02-10
ATE234469T1 (de) 2003-03-15
PL331612A1 (en) 1999-08-02
AU720626B2 (en) 2000-06-08
CA2263443C (en) 2004-03-30
EP0922226B1 (de) 2003-03-12
EP0922226A1 (de) 1999-06-16
EA001033B1 (ru) 2000-08-28
EP0922226B2 (de) 2008-06-25
AU4298897A (en) 1998-03-06
US6875616B1 (en) 2005-04-05
PL186810B1 (pl) 2004-02-27
CN1233326A (zh) 1999-10-27

Similar Documents

Publication Publication Date Title
PT922226E (pt) Processo para a avaliacao do estado de um organismo por meio de medicao de peptideos
DK0901634T3 (da) System til bestemmelse af mindst en parameter i mindst en prøve af en fysiologisk væske samt en kassette
BR0006035A (pt) Mancal com dispositivo para detectar pulsos magnéticos de um codificador e o dispositivo compreendendo vários elementos sensores alinhados
BR9612459A (pt) Sistema de teste de poço automático de processo de operação
BR9607098A (pt) Novos inibidores seletivos de neuraminidas virais ou bacterianas
BR9611405A (pt) Processo e aparelho para obtenção de dados representativos do desempenho operacional de um dispositivo de controle de processo, sistema de controle para avaliação da operação de um dispositivo de controle utilizado para controlar um processo, e, processo para aquisição de dados.
ES2178706T3 (es) Metodo de deteccion de color.
ATE278934T1 (de) Verteilte spannung- und temperaturmesssystem
DE69839362D1 (de) Hochgeschwindigkeits-Datenerfassungssystem mit Mikrostreifen-Gaskammer und Verfahren zum Messen von Proben unter Verwendung des Systems
FI883305A7 (fi) Menetelmä ja laite kaasuvuodon ilmaisemiseksi.
FI915150A7 (fi) Menetelmät, reagenssit ja testikäyttöpakkaukset biologisten yksiköiden alapopulaatioiden määrittämiseksi
AR018821A1 (es) Procedimiento para la determinacion de antibioticos con nucleo beta-lactama en un liquido biologico
NO901349L (no) Fremgangsmaate for maaling eller testing.
SE8802944D0 (sv) Materials for patch testing
DE68914617D1 (de) Nachweisvorrichtung für Kathodenlumineszenzanalyse.
WO1999030165A3 (en) Processes for identifying a solvent condition suitable for determining a biophysical property of a protein
DE69431802D1 (de) Detektierung und artbestimmung von campylobacter
ES2186121T3 (es) Mejora de los resultados de los dosificados de inmunodeteccion gracias al empleo de varios trazadores.
BR9917198B1 (pt) dispositivo de teste para detecção ou enumeração de microorganismos, e, processo para utilizar um dispositivo de teste.
DE59002164D1 (de) Rastertunnelmikroskop mit einrichtungen zur erfassung von von der probe herkommender elektronen.
DE59604894D1 (de) Testsystem zur erfassung der aktivität von nk-zellen
FR2799281B1 (fr) Procede et dispositif de detection d'une reaction de reconnaissance moleculaire
FR2728904B1 (fr) Reactif peptidique permettant de detecter une infection primaire a virus d'epstein-barr par recherche des anticorps correspondants, et procede d'utilisation de ce reactif
DK1224222T3 (da) Chemokinreceptor
TR199902757T2 (xx) Grup O HIV-1 vir�slerine ba�l� enfeksiyonlar�n tespiti i�in biyolojik testlerde kullan�labilen sentetik peptitler.